Treatment with homoharringtonine and cytarabine in patients with high risk acute myelogenous leukemia (AML).

被引：0
|
作者：
Chang, Naibai [1 ]
Wei, Jianping [1 ]
Zhao, Shengming [1 ]
Liu, Hui [1 ]
Fan, Yun [1 ]
Li, Jiangtao [1 ]
Xu, Xiaodong [1 ]
Gu, Xichun [1 ]
机构：
[1] Beijing Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4555
引用
收藏
页码：218B / 218B
页数：1
相关论文
共 50 条
  • [31] Comparative Efficacy of Homoharringtonine Plus Cytarabine and Decitabine in Patients with MDS/AML
    Liu, Yuejian
    Chen, Feili
    Guo, Xutao
    Shi, Pengcheng
    Zha, Jie
    Fan, Zhiping
    Huang, Fen
    Xu, Bing
    BLOOD, 2012, 120 (21)
  • [32] Venothromboembolism (VTE) in patients (pts) with acute myelogenous leukemia (AML)
    Luong, N. V.
    Kroll, M.
    Faderi, S.
    Yang, D.
    Zalpour, A.
    Nguyen, K. T.
    Verma, D.
    Borthakur, G.
    Kantarjian, H.
    Vu, K. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] COMPARATIVE EFFICACY OF HOMOHARRINGTONINE PLUS CYTARABINE AND DECITABINE IN PATIENTS WITH MDS/AML
    Xu, B.
    Liu, Y.
    Chen, F.
    Shi, P.
    Guo, X.
    Zha, J.
    Fan, Z.
    Huang, F.
    Zhou, S.
    HAEMATOLOGICA, 2013, 98 : 584 - 584
  • [34] Final Report of a Phase II Trial of Vorinostat, Idarubicin and Cytarabine In Previously Untreated Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
    Garcia-Manero, Guillermo
    Tambaro, Francesco Paolo
    Bekele, Nebiyou
    Jabbour, Elias
    Borthakur, Gautam
    Ravandi, Farhad
    Konopleva, Marina
    Kadia, Tapan
    Cortes, Jorge E.
    Yang, Hui
    Brandt, Mark
    Pierce, Sherry A.
    Newsome, Willie Mae
    Kantarjian, Hagop
    BLOOD, 2010, 116 (21) : 903 - 904
  • [35] A homoharringtonine-based regimen for childhood acute myelogenous leukemia
    Tang, JY
    Xue, HL
    Pan, C
    Chen, J
    Gu, LJ
    Zhao, HJ
    MEDICAL AND PEDIATRIC ONCOLOGY, 2003, 41 (01): : 70 - 72
  • [36] Phase I study of a single high dose of liposomal daunorubicin combined with high dose cytarabine for adult patients with relapsed/refractory acute myelogenous leukemia (AML).
    Maslak, P
    Weiss, M
    Jurcic, J
    Cathcart, K
    Heaney, M
    Berman, E
    Soignet, S
    Scheinberg, D
    Ward, S
    BLOOD, 2000, 96 (11) : 325A - 325A
  • [37] High-risk acute myelogenous leukemia: treatment today ... and tomorrow
    Schiller, Gary J.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2013, : 201 - 208
  • [38] High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML)
    Larson, Sarah M.
    Campbell, Nicholas P.
    Huo, Dezheng
    Artz, Andrew
    Zhang, Yanming
    Gajria, Devika
    Green, Margaret
    Weiner, Howie
    Daugherty, Christopher
    Odenike, Olatoyosi
    Godley, Lucy A.
    Hyjek, Elizabeth
    Gurbuxani, Sandeep
    Thirman, Michael
    Sipkins, Dorothy
    Van Besien, Koen
    Larson, Richard A.
    Stock, Wendy
    LEUKEMIA & LYMPHOMA, 2012, 53 (03) : 445 - 450
  • [39] HIGH-DOSE CYTARABINE AND DAUNORUBICIN INDUCTION AND POSTREMISSION CHEMOTHERAPY FOR THE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA IN ADULTS
    PHILLIPS, GL
    REECE, DE
    SHEPHERD, JD
    BARNETT, MJ
    BROWN, RA
    FREILAHR, DA
    KLINGEMANN, HG
    BOLWELL, BJ
    SPINELLI, JJ
    HERZIG, RH
    HERZIG, GP
    BLOOD, 1991, 77 (07) : 1429 - 1435
  • [40] HIGH-DOSE CYTOSINE-ARABINOSIDE IN THE TREATMENT OF REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML)
    GISSLINGER, H
    PREIS, P
    LINKESCH, W
    BLUT, 1985, 51 (03): : 210 - 210
12345